PDS Biotechnology Corporation
PDS Biotechnology Corporation (PDSB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pdsb · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PDS Biotechnology CorporationYou PDSB | $56M | N/A | — | -$0.60 |
 Annovis Bio, Inc. ANVS | $36M | N/A | — | -$1.40 |
 Actinium Pharmaceuticals, Inc. ATNM | $33M | N/A | — | -$1.09 |
 FibroGen, Inc. FGEN | $37M | 0.19x | — | $45.38 |
 INmune Bio, Inc. INMB | $34M | N/A | — | -$1.73 |
 Kezar Life Sciences, Inc. KZR | $54M | N/A | — | -$7.66 |
 LAVA Therapeutics N.V. LVTX | $46M | N/A | — | -$0.94 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PDS Biotechnology Corporation (PDSB) measures how much investors pay for each dollar of the company's trailing earnings. PDSB's current PE ratio of N/A is calculated by dividing its stock price of $1.01 by its TTM earnings per share of -$0.60.
Frequently asked questions
PDSB pe ratio · 6 questionsPDSB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.01 and TTM EPS of -$0.60. Data sourced from Financial Modeling Prep via PDSB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PDS Biotechnology Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09